Article

Carl Zeiss Meditec to acquire Acri.Tec AG

Jena, Germany-Zeiss Meditec hopes to obtain Acri.Tec AG, a leading company in implants for ophthalmic surgery.

Jena, Germany-Carl Zeiss Meditec, a medical technology provider, hopes to obtain Acri.Tec AG, a leading company in implants for ophthalmic surgery. In 2006, Acri.Tec AG's sales totaled €15.4 million in innovative implants and other products for ophthalmic surgery.

The actual purchase price will be determined once it is reduced by net financial debt at the closing date. October 2007 is when the transaction should be completed as long as the German anti-trust authority approves it and contractually agreed conditions have been met.

Ulrich Krauss, president and CEO of Carl Zeiss Meditec, in a prepared statement said Acri.Tec has a name as well recognized as Zeiss and is an important step in the expansion of its product portfolio, especially for innovative IOLs.

Besides devices for diagnosis, treatment and aftercare, the acquisition will also incorporate IOLs for cataract treatments and to correct vision defects. The transaction will also strengthen Carl Zeiss Meditec's business in Germany, according to Krauss.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.